NCT02259595View on ClinicalTrials.gov

Study to Determine the Safety, Tolerability, and Pharmacokinetic Profile of HPN-07 and HPN-07 Plus NAC

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

January 31, 2015

Study Completion Date

February 28, 2015

Conditions
Hearing LossSensorineural Hearing LossNoise-Induced Hearing Loss
Interventions
DRUG

HPN-07

500-1,500 mg oral capsules administered in a single dose

DRUG

NAC

1,200mg NAC administered via oral capsule in single dose

DRUG

Placebo

placebo oral capsule

Trial Locations (1)

27612

Wake Research Associates, Raleigh

Sponsors
All Listed Sponsors
lead

Otologic Pharmaceutics, Inc.

INDUSTRY

NCT02259595 - Study to Determine the Safety, Tolerability, and Pharmacokinetic Profile of HPN-07 and HPN-07 Plus NAC | Biotech Hunter | Biotech Hunter